GlassScriptPhysician profile
Melissa Kohner
NPI 1295255784
$2,366.05
in general payments reported to CMS, 2019-2025
34 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2022: $290 · 2023: $476 · 2024: $499 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,477 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,476.69 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $245.80 | 2022-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $213.52 | 2019-2024 | |
| Edwards Lifesciences Corporation | $135.29 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $120.79 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $102.72 | 2019 | |
| Novo Nordisk INC | $102.34 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $101.07 | 2022 | |
| Astellas Pharma US INC | $99.92 | 2023-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $97.68 | 2024 | Voquezna |
| Pfizer INC. | $95.43 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $87.21 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.66 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $71.45 | 2019 | |
| Xeris Pharmaceuticals, INC. | $64.54 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Merck Sharp & Dohme LLC | $61.67 | 2023-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $61.24 | 2023-2025 | Nexplanon, Nuvaring |
| Astrazeneca Pharmaceuticals LP | $55.96 | 2022-2025 | Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.44 | 2024-2025 | Caplyta |
| Dexcom, INC. | $50.57 | 2022-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $48.95 | 2022-2024 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $48.74 | 2023 | Austedo Xr, Austedo |
| Abbott Laboratories | $41.77 | 2024-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $40.64 | 2023-2024 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $35.67 | 2025 | |
| Exact Sciences Corporation | $34.46 | 2024-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $34.06 | 2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $33.53 | 2019-2024 | Spravato |
| Amgen INC. | $30.71 | 2024 | Prolia, Evenity |
| Mylan Specialty L.P. | $24.72 | 2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.40 | 2023 | Jardiance |
| Cipher Pharmaceuticals US LLC | $20.36 | 2025 | Spinosad, Natroba |
| Neurocrine Biosciences, INC. | $17.67 | 2025 | |
| Ucb, INC. | $16.83 | 2019 | |
| Axsome Therapeutics, INC. | $14.24 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Kohner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.